SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+3.98%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$741M
AUM Growth
+$99.3M
(+15%)
Cap. Flow
+$145M
Cap. Flow
% of AUM
19.51%
Top 10 Holdings %
Top 10 Hldgs %
44.76%
Holding
95
New
21
Increased
23
Reduced
18
Closed
26
Top Buys
| 1 |
FibroGen
FGEN
|
$21.9M |
| 2 |
Smith & Nephew
SNN
|
$20.5M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$19.3M |
| 4 |
Lantheus
LNTH
|
$15.5M |
| 5 |
CVS Health
CVS
|
$14.2M |
Top Sells
| 1 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$12.7M |
| 2 |
NeoGenomics
NEO
|
$9.19M |
| 3 |
CareDx
CDNA
|
$8.03M |
| 4 |
Cytosorbents Corp
CTSO
|
$6.5M |
| 5 |
C4 Therapeutics
CCCC
|
$6.1M |
Sector Composition
| 1 | Healthcare | 95.46% |
| 2 | Financials | 0.86% |
| 3 | Consumer Staples | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCXI
51
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.49M | 0.25% |
+68,320
| New | +$2.49M |
|
52
Viridian Therapeutics
VRDN
$1.59B
| $1.78M | 0.18% |
+90,000
| New | +$1.78M |
|
53
Immunic
IMUX
$79.4M
| $1.68M | 0.17% |
+175,000
| New | +$1.68M |
|
54
NovoCure
NVCR
$1.35B
| $1.67M | 0.17% |
22,275
-5,000
| -18% | -$375K |
|
55
CRISPR Therapeutics
CRSP
$4.82B
| $1.67M | 0.17% |
22,000
-70,214
| -76% | -$5.32M |
|
56
Avalo Therapeutics
AVTX
$139M
| $1.31M | 0.13% |
+267
| New | +$1.31M |
|
57
Liquidia Corp
LQDA
$2.52B
| $1.13M | 0.11% |
+231,485
| New | +$1.13M |
|
58
Arvinas
ARVN
$580M
| $904K | 0.09% |
+11,000
| New | +$904K |
|
59
Werewolf Therapeutics
HOWL
$62.6M
| $769K | 0.08% |
64,585
-498,811
| -89% | -$5.94M |
|
|
BCYC
60
Bicycle Therapeutics
BCYC
$492M
| $624K | 0.06% |
+10,250
| New | +$624K |
|
61
Fate Therapeutics
FATE
$115M
| $456K | 0.05% |
+7,800
| New | +$456K |
|
62
Celcuity
CELC
$2.3B
| $423K | 0.04% |
32,073
-51,615
| -62% | -$681K |
|
|
NGM
63
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $230K | 0.02% |
13,000
-28,000
| -68% | -$495K |
|
64
Beam Therapeutics
BEAM
$1.9B
| $227K | 0.02% |
2,850
-4,850
| -63% | -$386K |
|
65
Lyra Therapeutics
LYRA
$11.8M
| $44K | ﹤0.01% |
200
-4,112
| -95% | -$905K |
|
66
Editas Medicine
EDIT
$225M
| – | – |
-23,500
| Closed | -$965K |
|
|
VIVO
67
DELISTED
Meridian Bioscience Inc
VIVO
| – | – |
-163,000
| Closed | -$3.14M |
|
68
Assembly Biosciences
ASMB
$185M
| – | – |
-93,500
| Closed | -$3.91M |
|
69
Astria Therapeutics
ATXS
$394M
| – | – |
-112,499
| Closed | -$994K |
|
70
Atea Pharmaceuticals
AVIR
$275M
| – | – |
-117,600
| Closed | -$4.12M |
|
71
Axogen
AXGN
$718M
| – | – |
-158,140
| Closed | -$2.5M |
|
|
72
CareDx
CDNA
$678M
| – | – |
-126,661
| Closed | -$8.03M |
|
|
CMPS
73
Compass Pathways
CMPS
$452M
| – | – |
-127,743
| Closed | -$3.82M |
|
74
Corcept Therapeutics
CORT
$7.52B
| – | – |
-155,000
| Closed | -$3.05M |
|
75
CytomX Therapeutics
CTMX
$350M
| – | – |
-261,050
| Closed | -$1.33M |
|